NeuroPace

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's product RNS system is designed for the treatment of medically refractory partial epilepsy includes implantable and external products. The company was founded by Robert Fischell, David Fischell, Tim Fischell, Scott Fischell, Rebecca L. Kuhn, Frank M. Fischer and Martha Morrell on November 19, 1997 and is headquartered in Mountain View, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeuroPace reports robust Q4 performance and outlines growth strategies

NeuroPace's Q4 call highlighted strong performance, strategic priorities for 2023, and challenges in maintaining gross margins. The company's focus on revenue growth drivers, market recovery, and new center expansions positions it well for future growth.

NeuroPace reports record revenue in Q1 2023, raises full-year guidance

NeuroPace delivered strong revenue growth in Q1 2023, with a positive outlook for the full year. The company faces challenges in managing operating expenses and sustaining profitability. However, opportunities lie in product distribution, clinical trials, and strategic growth initiatives.

NeuroPace excels in Q2, raises revenue guidance amid strategic growth

NeuroPace's Q2 performance reflects strong growth momentum and improved financial health, supported by strategic partnerships and effective expense management. The company's focus on expanding patient access and optimizing sales operations positions it well for continued success in 2023.

NeuroPace reports robust Q3 earnings, eyes strategic growth opportunities

NeuroPace's Q3 performance reflects strong revenue growth, improved margins, and prudent cost management, positioning the company for sustained success.
While facing challenges in net losses and operating expenses, NeuroPace's operational achievements and financial stability provide a solid foundation for future growth.
By addressing cost structures, leveraging market opportunities, and adapting to evolving market dynamics, NeuroPace can enhance profitability and drive long-term value creation.

NeuroPace reports robust revenue growth and strategic collaborations for 2024

NeuroPace's strong performance in Q4 2023 and full-year results demonstrate growth momentum.
Strategic collaborations and a focus on cost management are key strengths.
Challenges include managing expenses and market dynamics, but growth opportunities are present.
Overall, NeuroPace is well-positioned for revenue growth and transformative impact in 2024.

NeuroPace reports strong Q1 revenue growth and strategic collaborations

NeuroPace's Q1 2024 performance reflects revenue growth, margin improvements, and strategic collaborations.
The company faces challenges in maintaining margins, financial discipline, and closing the treatment gap.
Opportunities lie in expanding therapy access, market growth, and executing the growth strategy.
Overall, NeuroPace is on track to drive revenue through product sales and strategic initiatives.

NeuroPace reports robust Q2 earnings, eyes growth through strategic initiatives

NeuroPace's Q2 2024 performance reflects revenue growth, improved gross margin, and strategic initiatives driving future expansion and market penetration.
While facing challenges in managing operating expenses and maintaining margins, the company's strong cash position and growth strategy present opportunities for sustained growth.
Overall, NeuroPace's focus on innovation, market expansion, and financial prudence positions it well for future success in the neurotechnology sector.

NeuroPace reports robust Q3 earnings, eyes growth in epilepsy market

NeuroPace's Q3 2024 performance reflects solid revenue growth, operational improvements, and strategic focus on innovation and market expansion.
While facing challenges such as operating losses and competitive pressures, the company is well-positioned to leverage growth opportunities in the epilepsy treatment market.
With a strong financial position, effective leadership enhancements, and proactive investor engagement, NeuroPace is poised for continued growth and market success.
Strategic initiatives and upcoming events underscore the company's commitment to driving value for stakeholders and advancing its position in the industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.

NeuroPace (NPCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes NeuroPace (NPCE) a New Buy Stock

The mean of analysts' price targets for NeuroPace (NPCE) points to a 54.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade

NeuroPace, Inc. (NASDAQ:NPCE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Jeremy Feffer – Investor Relations Joel Becker – Chief Executive Officer Rebecca Kuhn – Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets Mike Kratky – Leerink Partners Vik Chopra – Wells Fargo Ross Osborn – Cantor Fitzgerald Michael Polark – Wolfe Research Operator Greetings and welcome to NeuroPace's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

NeuroPace, Inc. (NPCE) Q3 2024 Earnings Call Transcript

NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.28 per share a year ago.

NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates

The RNS System Post-Approval Study (PAS) is the largest prospective post-approval study in neuromodulation for patients with drug - resistant focal epilepsy

NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy

NeuroPace (NPCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength?

MOUNTAIN VIEW, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024

Appoints experienced people leader as Vice President of Human Resources Appoints experienced people leader as Vice President of Human Resources

NeuroPace Continues to Strengthen Management Team

Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately.

NeuroPace Strengthens Management Team with Two Key Appointments

MOUNTAIN VIEW, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in the following two healthcare investor conferences in September.

NeuroPace Announces Participation at Two Upcoming Healthcare Investor Conferences

MOUNTAIN VIEW, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in two healthcare conferences in September. NeuroPace management will host one-on-one meetings with investors at the Wells Fargo 2024 Healthcare Conference, on Wednesday, September 4 in Boston, MA.

NeuroPace to Participate in Upcoming Healthcare Conferences in September

NeuroPace, Inc. aims to improve the lives of epilepsy patients with RNS technology, addressing drug-resistant epilepsy. The company has seen revenue growth, but continues to post losses nonetheless. NeuroPace stock is displaying substantial volatility and looks interesting on a highly speculative basis, anticipating wider approval of RNS.

NeuroPace: Only For Those With Strong Nerves

NeuroPace's (NPCE) top and bottom lines outpace estimates in the second quarter.

NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up

NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Vikramjeet Chopra - Wells Fargo Ross Osborn - Cantor Fitzgerald Mike Kratky - Leerink Partners Frank Takkinen - Lake Street Capital Markets Robert Marcus - JP Morgan Michael Polark - Wolfe Research Operator Good afternoon and welcome to NeuroPace's Second Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.

NeuroPace, Inc. (NPCE) Q2 2024 Earnings Call Transcript

MOUNTAIN VIEW, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter of 2024 after market close on Tuesday, August 13, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

NeuroPace to Report Second Quarter 2024 Financial Results on August 13, 2024

NeuroPace, Inc. (NASDAQ:NPCE ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Mike Kratky - Leerink Partners Frank Takkinen - Lake Street Capital Markets Vik Chopra - Wells Fargo Ross Osborn - Cantor Fitzgerald Michael Polark - Wolfe Research Drew Ranieri - Morgan Stanley Operator Good afternoon and welcome to NeuroPace's First Quarter 2024 Conference Call. As a reminder, this call is being recorded.

NeuroPace, Inc. (NPCE) Q1 2024 Earnings Call Transcript

-- Revenue increased to $18.1 million in Q1 2024, a 25% increase over Q1 2023 -- -- Extended the maturity date of the Company's term loan by one year to September 30, 2026 --

NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update

MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 8, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024

MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will present at the Needham 23rd Annual Healthcare Conference, taking place virtually from April 8-11.

NeuroPace to Present at the Needham 23rd Annual Healthcare Conference

NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET

NeuroPace, Inc. (NPCE) Q4 2023 Earnings Call Transcript

-- Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4 2022 -- -- Revenue increased to $65.4 million in 2023, a 44% increase over 2022 --

NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million

Bioceres Crop Solutions Corp

Direct Digital Holdings

One of the best stocks for financial freedom over the past 30 years is Monster Beverage (NASDAQ: MNST ). Between Feb. 14, 1994, and Feb. 14, 2024, the energy drink maker's stock appreciated around 200,000%.

Financial Freedom Fighters: 3 Stocks to Liberate Your Portfolio

MOUNTAIN VIEW, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Tuesday, March 5, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for Q4 2023 and between $64.9 million and $65.4 million for full year 2023

NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates

NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy

News for NeuroPace Stock (NPCE)